Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ: PODD )

255.44 +10.77 (+4.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Insulet Corporation - Common Stock

< Previous 1 2 3 4 Next >
Insulet to Host Investor Day on June 5, 2025
From Insulet Corporation
Via Business Wire
Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year
From Insulet Corporation
Via Business Wire
Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe
From Insulet Corporation
Via Business Wire
Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From Insulet Corporation
Via Business Wire
Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
From Insulet Corporation
Via Business Wire
Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.
From Insulet Corporation
Via Business Wire
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)
From Insulet Corporation
Via Business Wire
Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November
From Insulet Corporation 
Via Business Wire
Omnipod® 5 App for iPhone® Now Fully Available in the United States
From Insulet Corporation
Via Business Wire
Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024
From Insulet Corporation
Via Business Wire
Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes
From Insulet Corporation
Via Business Wire
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia
From Insulet Corporation
Via Business Wire
Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year
From Insulet Corporation
Via Business Wire
Insulet Reports Preliminary Second Quarter 2024 Revenue Results
From Insulet Corporation
Via Business Wire
Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Insulet Corporation
Via Business Wire
Insulet’s SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
From Insulet Corporation
Via Business Wire
Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
From Insulet Corporation
Via Business Wire
Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates
From Insulet Corporation
Via Business Wire
Insulet to Present at the Jefferies Global Healthcare Conference
From Insulet Corporation
Via Business Wire
Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year
From Insulet Corporation
Via Business Wire
Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
From Insulet Corporation
Via Business Wire
Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
From Insulet Corporation
Via Business Wire
Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
From Insulet Corporation
Via Business Wire
Are These 5 Undervalued Stocks Ready to Break Out?
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. 
Via MarketBeat
Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
From Insulet Corporation
Via Business Wire
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
From Insulet Corporation
Via Business Wire
Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)
From Insulet Corporation
Via Business Wire
Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
From Insulet Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.